Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

Published:2014-01 Issue:1 Volume:15 Page:69-77
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Westin Jason R,Chu Fuliang,Zhang Min,Fayad Luis E,Kwak Larry W,Fowler Nathan,Romaguera Jorge,Hagemeister Fredrick,Fanale Michelle,Samaniego Felipe,Feng Lei,Baladandayuthapani Veerabhadran,Wang Zhiqiang,Ma Wencai,Gao Yanli,Wallace Michael,Vence Luis M,Radvanyi Laszlo,Muzzafar Tariq,Rotem-Yehudar Rinat,Davis R Eric,Neelapu Sattva S

Funder

National Institutes of Health (NIH)

SSN

Leukemia and Lymphoma Society Specialized Center of Research

NIH Clinical and Translational Science Award

NIH Cancer Center Support

Publisher

Elsevier BV

Subject

Oncology

Reference43 articles.

1. The three Es of cancer immunoediting;Dunn;Annu Rev Immunol,2004

2. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells;Dave;N Engl J Med,2004

3. CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma;Wahlin;Clin Cancer Res,2007

4. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients;Alvaro;J Clin Oncol,2006

5. A novel strategy for rapid and efficient isolation of human tumor-specific CD4(+) and CD8(+) T-cell clones;Lee;J Immunol Methods,2008

Cited by 485 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sintilimab (anti-PD-1 antibody) combined with high-dose methotrexate, temozolomide, and rituximab (anti-CD20 antibody) in primary central nervous system lymphoma: a phase 2 study;Signal Transduction and Targeted Therapy;2024-09-04

2. Prediction of PD-L1 and Ki-67 status in primary central nervous system diffuse large B-cell lymphoma by diffusion and perfusion MRI: a preliminary study;BMC Medical Imaging;2024-08-26

3. Immune checkpoint inhibitors targeting PD-1/PD-L1 in the treatment of human lymphomas;Frontiers in Oncology;2024-07-18

4. Computational Approach for the Development of pH-Selective PD-1/PD-L1 Signaling Pathway Inhibition in Fight with Cancer;Cancers;2024-06-22

5. Immunotherapy in the Treatment of Cancer: Today and Tomorrow;Current Molecular Biology Reports;2024-05-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3